Akero Therapeutics Stock Doubles on Liver Disease Drug Trial Results

Trending 2 weeks ago

Key Takeaways

  • Akero Therapeutics shares traded adjacent their all-time precocious arsenic nan drugmaker reported affirmative results successful a study of its curen for liver disease.
  • The drug, known arsenic EFX, helped reverse cirrhosis of nan liver successful patients pinch metabolic dysfunction-associated steatohepatitis (MASH).
  • CEO Dr. Andrew Cheng said EFX has "transformational potential" successful fighting nan disease.

Shares of Akero Therapeutics (AKRO) doubled Monday erstwhile nan pharmaceutical patient that focuses connected metabolic illnesses reported affirmative results from a study of its experimental curen for liver disease.

The institution said a 96-week Phase 2b study of those afflicted pinch cirrhosis caused by metabolic dysfunction-associated steatohepatitis (MASH) and fixed a 50mg dosage of its supplier efruxifermin (EFX) showed that 39% knowledgeable reversal of cirrhosis pinch nary worsening of MASH. That compares to conscionable 15% of those fixed placebo.

Akero noted that a subgroup of patients who were not connected GLP-1 weight-loss medicines, specified arsenic Novo Nordisk's (NVO) Wegovy and Eli Lilly's (LLY) Zepbound, had moreover amended outcomes, indicating that those narcotics were not nan root of nan improvement.

Dr. Mazen Nourredin, nan main interrogator of nan study, said until now, "we've not had nan imaginable of an effective curen for compensated cirrhosis owed to MASH." Dr. Nourredin added, "Now we person logic to beryllium optimistic astir nan early imaginable of EFX arsenic a much-needed curen for cirrhosis, if approved."

CEO Dr. Andrew Cheng explained that EFX has "transformational potential," and nan institution is continuing information of nan curen successful an ongoing Phase 3 trial.

Akero Therapeutics shares traded adjacent their all-time precocious group much than 2 years ago.

TradingView

Source investopedia
investopedia